A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution.
Sign Up to like & getrecommendations! Published in 2017 at "Cell reports"
DOI: 10.1016/j.celrep.2017.07.006
Abstract: Combinatorial inhibition of effector and feedback pathways is a promising treatment strategy for KRAS mutant cancers. However, the particular pathways that should be targeted to optimize therapeutic responses are unclear. Using CRISPR/Cas9, we systematically mapped… read more here.
Keywords: mutant cancers; therapeutic cooperativity; landscape therapeutic; cancers reveals ... See more keywords
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers
Sign Up to like & getrecommendations! Published in 2019 at "Science Advances"
DOI: 10.1126/sciadv.aax1738
Abstract: BAP1 regulates developmental switch in lineages commonly affected by BAP1-mutant cancers. The BAP1 tumor suppressor is mutated in many human cancers such as uveal melanoma, leading to poor patient outcome. It remains unclear how BAP1… read more here.
Keywords: mutant cancers; bap1 regulates; bap1; switch ... See more keywords
Abstract A010: Using oncogenic pathway agonism to sensitize RAS-mutant cancers to immunotherapy
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-a010
Abstract: Overall, some 30% of human cancers are driven by mutant RAS proteins, which have proven relatively difficult to target. While immunotherapy is effective for NRAS-mutant melanoma, no options exist for resistant disease, and mutant KRAS-driven… read more here.
Keywords: oncogenic pathway; ras mutant; sensitize ras; pathway agonism ... See more keywords
(R)-2-hydroxyglutarate inhibits KDM5 histone lysine demethylases to drive transformation in IDH-mutant cancers.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-22-0825
Abstract: Oncogenic mutations in isocitrate dehydrogenase (IDH)-1 and -2 occur in a wide range of cancers, including acute myeloid leukemia (AML) and glioma. Mutant IDH enzymes convert 2-oxoglutarate (2OG) to (R)-2-hydroxyglutarate ((R)-2HG)), an oncometabolite that is… read more here.
Keywords: idh mutant; histone lysine; idh; mutant cancers ... See more keywords
Non-Oncogene Addiction of KRAS-Mutant Cancers to IL-1β via Versican and Mononuclear IKKβ
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15061866
Abstract: Simple Summary Kirsten rat sarcoma virus (KRAS)-mutant cancers are frequent, metastatic, lethal, and largely undruggable. The aim of this study was to investigate the pathways through which KRAS-mutant cancers foster their growth, thereby unravelling novel… read more here.
Keywords: non oncogene; kras mutant; mutant cancers; addiction ... See more keywords